Literature DB >> 1422689

Treatment of advanced localised prostatic cancer by orchiectomy, radiotherapy, or combined treatment. A Medical Research Council Study. Urological Cancer Working Party--Subgroup on Prostatic Cancer.

G J Fellows1, P B Clark, L L Beynon, J Boreham, C Keen, M C Parkinson, R Peto, J N Webb.   

Abstract

A total of 277 patients with apparently localised prostatic cancer (T2-T4 NXMO) were allocated at random to receive radiotherapy alone (88), orchiectomy alone (90) and combined therapy (99) between 1980 and 1985. The main outcome measures were survival, time to appearance of metastases and treatment of local disease progression by further transurethral resection. Orchiectomy, whether alone or with radiotherapy, produced a significant delay in detection of metastases when compared with radiotherapy alone. There were no statistically significant differences between the 3 treatment groups in local disease control or in overall survival.

Entities:  

Mesh:

Year:  1992        PMID: 1422689     DOI: 10.1111/j.1464-410x.1992.tb15736.x

Source DB:  PubMed          Journal:  Br J Urol        ISSN: 0007-1331


  11 in total

1.  High-risk prostate cancer: is androgen deprivation monotherapy still appropriate?

Authors:  Vahakn B Shahinian
Journal:  Asian J Androl       Date:  2012-02-06       Impact factor: 3.285

2.  Radiation therapy to the primary tumor in locally advanced prostate cancer is not "closing the barn door after the horse has bolted".

Authors:  Nicholas G Zaorsky; Mark A Hallman; Marc C Smaldone
Journal:  Ann Transl Med       Date:  2015-10

Review 3.  Screening for prostate cancer. Implications for drug therapy.

Authors:  R H Harwood
Journal:  Drugs Aging       Date:  1995-05       Impact factor: 3.923

4.  Overview of randomized controlled treatment trials for clinically localized prostate cancer: implications for active surveillance and the United States preventative task force report on screening?

Authors:  Mack Roach; Kimberly Thomas
Journal:  J Natl Cancer Inst Monogr       Date:  2012-12

Review 5.  Cancer of the prostate.

Authors:  D P Dearnaley
Journal:  BMJ       Date:  1994-03-19

6.  Characteristics of urologists predict the use of androgen deprivation therapy for prostate cancer.

Authors:  Vahakn B Shahinian; Yong-fang Kuo; Jean L Freeman; Eduardo Orihuela; James S Goodwin
Journal:  J Clin Oncol       Date:  2007-12-01       Impact factor: 44.544

Review 7.  Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer.

Authors:  S Kumar; M Shelley; C Harrison; B Coles; T J Wilt; M D Mason
Journal:  Cochrane Database Syst Rev       Date:  2006-10-18

8.  Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial.

Authors:  Padraig Warde; Malcolm Mason; Keyue Ding; Peter Kirkbride; Michael Brundage; Richard Cowan; Mary Gospodarowicz; Karen Sanders; Edmund Kostashuk; Greg Swanson; Jim Barber; Andrea Hiltz; Mahesh K B Parmar; Jinka Sathya; John Anderson; Charles Hayter; John Hetherington; Matthew R Sydes; Wendy Parulekar
Journal:  Lancet       Date:  2011-11-02       Impact factor: 79.321

Review 9.  Radiotherapy for t3 prostate cancer.

Authors:  Andrew Bayley; Mary K Gospodarowicz
Journal:  Curr Urol Rep       Date:  2003-06       Impact factor: 2.862

10.  No supra-additive effects of goserelin and radiotherapy on clonogenic survival of prostate carcinoma cells in vitro.

Authors:  Robert M Hermann; Dag Schwarten; Stefanie Fister; Carsten Grundker; Margret Rave-Frank; Mirko Nitsche; Andrea Hille; Paul Thelen; Heinz Schmidberger; Hans Christiansen
Journal:  Radiat Oncol       Date:  2007-08-26       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.